Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial.

Negar ToroghiLadan AbbasianAnahid NourianEffat Davoudi-MonfaredHossein KhaliliMalihe HasannezhadFereshteh GhiasvandSirous JafariHamid Emadi-KouchakMir Saeed Yekaninejad

Published in: Pharmacological reports : PR (2021)

Higher doses of dexamethasone not only failed to improve efficacy but also resulted in an increase in the number of adverse events and worsen survival in hospitalized patients with moderate to severe COVID-19 compared to the low-dose dexamethasone. (IRCT20100228003449N31).

Keyphrases

low dose
high dose
coronavirus disease
sars cov
respiratory syndrome coronavirus
early onset
clinical trial